Developer docs
API playgroundTry for free, no card

Search company profiles

NPS Pharmaceuticals

Full company profile

uuid003esyf

Namestring
NPS Pharmaceuticals
Legal namestring
Takeda Pharmaceutical Company Limited
Websiteurl
npsp.com
Company typeenum
Public
Founded yearint
1986
Descriptiontext

NPS Pharmaceuticals was a U.S.-based, rare-disease-focused biopharmaceutical company founded in 1986 and headquartered in Bedminster, New Jersey. The company developed and commercialized specialty therapeutics for ultra-rare conditions, most notably Gattex/Revestive (teduglutide) for short bowel syndrome and Natpara (parathyroid hormone) for hypoparathyroidism. Its commercial model centered on selling high-priced orphan drugs to a small but clinically dependent patient population through specialty pharmacy and physician channels, generating revenue via direct prescription sales. NPS was acquired by Takeda Pharmaceutical Company Limited in 2015 for approximately $5.2 billion and was subsequently delisted from NASDAQ; its products and capabilities were integrated into Takeda's rare disease franchise. Following the acquisition, NPS ceased to operate as an independent reporting entity, and the data now attributed to the NPS profile largely reflects its parent Takeda's global pharmaceutical operations across 70+ countries, including a robust pipeline in neuroscience, immunology, oncology, and rare diseases. As of mid-2026, the inherited NPS capabilities continue to be exercised through Takeda's enterprise field sales organization, global manufacturing infrastructure (including facilities referenced in legacy NPS production), and Phase 3 pipeline assets such as oveporexton for narcolepsy Type 1 and zasocitinib for psoriasis.

Short descriptiontext

NPS Pharmaceuticals is a former U.S. rare-disease biopharmaceutical company, founded in 1986 and acquired by Takeda in 2015 for ~$5.2 billion, whose Gattex/Revestive and Natpara products for short bowel syndrome and hypoparathyroidism now operate within Takeda's global rare disease franchise.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersBedminster, United States
HQ citystring
Bedminster
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rare disease therapeutics, specialty pharmaceuticals, biologics manufacturing, orphan drug development, prescription drug pipeline
Industry2 codes
PRIMARYHLAIAIAJ
Rare Endocrine & Growth Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAN
Rare Pediatric & Congenital Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Specialty Pharmaceuticals (Rare Disease Therapeutics)
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Prescription Pharmaceuticals
TypeOne Time License
Description

Takeda generates revenue through the development, manufacture, and sale of prescription pharmaceutical products globally. Revenue comes from both proprietary in-house developed drugs and acquired product lines including former NPS Pharmaceuticals products like Gattex/Revestive and Natpara.

takeda.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1TakedaEdge
Description

A generational promise initiative where Takeda leads with bold reinvention for a healthier world, embracing cutting-edge science, technology and partnerships to create new standards of care.

takeda.com
Core offering1 text field

NPS Pharmaceuticals developed and commercialized prescription therapeutics for rare diseases, most notably Gattex/Revestive (teduglutide) for short bowel syndrome and Natpara (parathyroid hormone) for hypoparathyroidism. The company operated an internal R&D pipeline targeting rare and specialty disease indications and relied on proprietary drug development and advanced manufacturing processes. Following its 2015 acquisition by Takeda, these products are sold through Takeda's global pharmaceutical commercial organization.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Oveporexton showed improved daily function, cognition, and nighttime sleep for people with narcolepsy Type 1 in pivotal studies
+1 more record
Product overview1 text field

No product information for NPS Pharmaceuticals found in the source data. The source data is from Takeda Pharmaceuticals website and does not contain information about NPS Pharmaceuticals products or services.

Product and service2 records
1Gattex/Revestive (teduglutide)
CategoryRare Disease Therapeutics
Description

A proprietary GLP-2 analog indicated for the treatment of short bowel syndrome (SBS) in adult and pediatric patients who are dependent on parenteral support. It is prescribed by specialists (e.g., gastroenterologists) for patients with rare gastrointestinal conditions.

2Natpara (parathyroid hormone)
CategoryRare Disease Therapeutics
Description

A recombinant parathyroid hormone product indicated as an adjunct to calcium and vitamin D for the treatment of hypoparathyroidism in adult patients who cannot be adequately controlled on calcium and vitamin D alone. Used by endocrinologists managing patients with this rare endocrine disorder.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1NPS Pharmaceuticals
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2015-01-01
Description

Takeda acquired NPS Pharmaceuticals in 2015 for approximately $5.2 billion, gaining control of NPS's rare disease portfolio including Gattex/Revestive (teduglutide) for short bowel syndrome and Natpara (parathyroid hormone) for hypoparathyroidism. This acquisition strengthened Takeda's rare disease franchise and expanded its specialty pharma capabilities.

takeda.com
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Pre-acquisition rare-disease leader acquired by Takeda in 2019. Operates within the same Takeda parent as NPS and represents the larger rare-disease incumbent under the same corporate umbrella.

TypeDirect peer
Description

Specialty biopharmaceutical company focused exclusively on rare diseases, with a portfolio of enzyme replacement and gene therapies addressing small patient populations — directly comparable business model and orphan-drug strategy to NPS.

TypeEmerging player
Description

Clinical-stage and commercial rare-disease biotech with a focus on lysosomal storage disorders and rare-chemistry therapies. Comparable as a smaller, emerging rare-disease specialist building an orphan franchise.

TypeDirect peer
Description

Specialty pharma focused on serious diseases with high unmet need (cystic fibrosis, sickle cell, pain). Comparable as a rare/specialty-disease-focused innovator with concentrated product franchises.

TypeDirect peer
Description

Rare-disease specialist built around high-priced biologics for ultra-rare conditions, later acquired by AstraZeneca. Closely mirrors NPS's rare-disease, high-price-per-patient, biologic-led model.

TypeDirect peer
Description

European specialty biopharma focused on rare diseases, particularly in immunology, hematology, and endocrinology. Closely aligned with NPS's rare-endocrine and orphan-biologic positioning.

TypeBroad incumbent
Description

Pioneering rare-disease franchise within Sanofi, with a broad orphan-drug portfolio across lysosomal storage, oncology, and immunology. Larger incumbent operating in adjacent rare-disease categories.

TypeDirect peer
Description

Pure-play rare-disease biotech developing and commercializing therapies for rare and ultra-rare genetic conditions. Directly comparable orphan-drug commercial and development model.

TypeDirect peer
Description

Specialty pharma division focused exclusively on rare diseases, including endocrine and metabolic disorders. Directly comparable orphan-disease commercial strategy and patient-by-patient distribution model.

TypeEmerging player
Description

Rare-disease biotech with FDA-approved therapies for ultra-rare conditions, acquired by Biogen in 2023. Comparable exit trajectory and rare-disease commercialization model to NPS.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NPS Pharmaceuticals

Specialty Pharmaceuticals (Rare Disease Therapeutics)npsp.com

NPS Pharmaceuticals is a former U.S. rare-disease biopharmaceutical company, founded in 1986 and acquired by Takeda in 2015 for ~$5.2 billion, whose Gattex/Revestive and Natpara products for short bowel syndrome and hypoparathyroidism now operate within Takeda's global rare disease franchise.

What NPS Pharmaceuticals does

NPS Pharmaceuticals was a U.S.-based, rare-disease-focused biopharmaceutical company founded in 1986 and headquartered in Bedminster, New Jersey. The company developed and commercialized specialty therapeutics for ultra-rare conditions, most notably Gattex/Revestive (teduglutide) for short bowel syndrome and Natpara (parathyroid hormone) for hypoparathyroidism. Its commercial model centered on selling high-priced orphan drugs to a small but clinically dependent patient population through specialty pharmacy and physician channels, generating revenue via direct prescription sales. NPS was acquired by Takeda Pharmaceutical Company Limited in 2015 for approximately $5.2 billion and was subsequently delisted from NASDAQ; its products and capabilities were integrated into Takeda's rare disease franchise. Following the acquisition, NPS ceased to operate as an independent reporting entity, and the data now attributed to the NPS profile largely reflects its parent Takeda's global pharmaceutical operations across 70+ countries, including a robust pipeline in neuroscience, immunology, oncology, and rare diseases. As of mid-2026, the inherited NPS capabilities continue to be exercised through Takeda's enterprise field sales organization, global manufacturing infrastructure (including facilities referenced in legacy NPS production), and Phase 3 pipeline assets such as oveporexton for narcolepsy Type 1 and zasocitinib for psoriasis.

NPS Pharmaceuticals firmographics

Firmographics
Name
NPS Pharmaceuticals
Legal name
Takeda Pharmaceutical Company Limited
Website
https://npsp.com
Company type
Public
Founded year
1986
Operating status
Operating
Headcount range
101–250 employees
Short description
NPS Pharmaceuticals is a former U.S. rare-disease biopharmaceutical company, founded in 1986 and acquired by Takeda in 2015 for ~$5.2 billion, whose Gattex/Revestive and Natpara products for short bowel syndrome and hypoparathyroidism now operate within Takeda's global rare disease franchise.
Ownership category
akta.pro rank

NPS Pharmaceuticals industry classification

Industry
Product category
Specialty Pharmaceuticals (Rare Disease Therapeutics)
NAICS
Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAIAJ
Rare Endocrine & Growth Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAN
Rare Pediatric & Congenital Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Rare disease therapeutics
  • Specialty pharmaceuticals
  • Biologics manufacturing
  • Orphan drug development
  • Prescription drug pipeline

Where NPS Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Bedminster
HQ country
United States
HQ region
North America

Offices4 records

Markets served

NPS Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain

Revenue model

  1. Prescription Pharmaceuticals: Takeda generates revenue through the development, manufacture, and sale of prescription pharmaceutical products globally. Revenue comes from both proprietary in-house developed drugs and acquired product lines including former NPS Pharmaceuticals products like Gattex/Revestive and Natpara.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

NPS Pharmaceuticals product offering

Product offering

Core offering

NPS Pharmaceuticals developed and commercialized prescription therapeutics for rare diseases, most notably Gattex/Revestive (teduglutide) for short bowel syndrome and Natpara (parathyroid hormone) for hypoparathyroidism. The company operated an internal R&D pipeline targeting rare and specialty disease indications and relied on proprietary drug development and advanced manufacturing processes. Following its 2015 acquisition by Takeda, these products are sold through Takeda's global pharmaceutical commercial organization.

Product overview

No product information for NPS Pharmaceuticals found in the source data. The source data is from Takeda Pharmaceuticals website and does not contain information about NPS Pharmaceuticals products or services.

Differentiator

Problem solved

Functional benefit

Brands

  • TakedaEdge: A generational promise initiative where Takeda leads with bold reinvention for a healthier world, embracing cutting-edge science, technology and partnerships to create new standards of care.

Products and services

  • Gattex/Revestive (teduglutide) A proprietary GLP-2 analog indicated for the treatment of short bowel syndrome (SBS) in adult and pediatric patients who are dependent on parenteral support. It is prescribed by specialists (e.g., gastroenterologists) for patients with rare gastrointestinal conditions.
  • Natpara (parathyroid hormone) A recombinant parathyroid hormone product indicated as an adjunct to calcium and vitamin D for the treatment of hypoparathyroidism in adult patients who cannot be adequately controlled on calcium and vitamin D alone. Used by endocrinologists managing patients with this rare endocrine disorder.

Quantifiable outcome

  • Oveporexton showed improved daily function, cognition, and nighttime sleep for people with narcolepsy Type 1 in pivotal studies
  • +1 more outcomes

Companies that use NPS Pharmaceuticals

Customer profile

Segments1 record

Ideal customer profiles1 record

NPS Pharmaceuticals technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

NPS Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • NPS PharmaceuticalscoreStrategic or Co-development Partner · 1 January 2015Takeda acquired NPS Pharmaceuticals in 2015 for approximately $5.2 billion, gaining control of NPS's rare disease portfolio including Gattex/Revestive (teduglutide) for short bowel syndrome and Natpara (parathyroid hormone) for hypoparathyroidism. This acquisition strengthened Takeda's rare disease franchise and expanded its specialty pharma capabilities.

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

NPS Pharmaceuticals competitors and assessment

Company assessment

Broad incumbents

  • Shire (now part of Takeda): Pre-acquisition rare-disease leader acquired by Takeda in 2019. Operates within the same Takeda parent as NPS and represents the larger rare-disease incumbent under the same corporate umbrella.
  • Genzyme (Sanofi Rare Disease): Pioneering rare-disease franchise within Sanofi, with a broad orphan-drug portfolio across lysosomal storage, oncology, and immunology. Larger incumbent operating in adjacent rare-disease categories.

Direct peers

  • BioMarin Pharmaceutical: Specialty biopharmaceutical company focused exclusively on rare diseases, with a portfolio of enzyme replacement and gene therapies addressing small patient populations — directly comparable business model and orphan-drug strategy to NPS.
  • Vertex Pharmaceuticals: Specialty pharma focused on serious diseases with high unmet need (cystic fibrosis, sickle cell, pain). Comparable as a rare/specialty-disease-focused innovator with concentrated product franchises.
  • Alexion Pharmaceuticals (AstraZeneca Rare Disease): Rare-disease specialist built around high-priced biologics for ultra-rare conditions, later acquired by AstraZeneca. Closely mirrors NPS's rare-disease, high-price-per-patient, biologic-led model.
  • Swedish Orphan Biovitrum (Sobi): European specialty biopharma focused on rare diseases, particularly in immunology, hematology, and endocrinology. Closely aligned with NPS's rare-endocrine and orphan-biologic positioning.
  • Ultragenyx Pharmaceutical: Pure-play rare-disease biotech developing and commercializing therapies for rare and ultra-rare genetic conditions. Directly comparable orphan-drug commercial and development model.
  • Recordati Rare Diseases: Specialty pharma division focused exclusively on rare diseases, including endocrine and metabolic disorders. Directly comparable orphan-disease commercial strategy and patient-by-patient distribution model.

Emerging players

  • Amicus Therapeutics: Clinical-stage and commercial rare-disease biotech with a focus on lysosomal storage disorders and rare-chemistry therapies. Comparable as a smaller, emerging rare-disease specialist building an orphan franchise.
  • Reata Pharmaceuticals (now Biogen): Rare-disease biotech with FDA-approved therapies for ultra-rare conditions, acquired by Biogen in 2023. Comparable exit trajectory and rare-disease commercialization model to NPS.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks4 records

Key highlights5 records

Customer concentration

NPS Pharmaceuticals social profiles

Digital presence

NPS Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NPS Pharmaceuticals leadership team

Management profile

Number of profiles

NPS Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NPS Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NPS Pharmaceuticals

What does NPS Pharmaceuticals do?

NPS Pharmaceuticals developed and commercialized prescription therapeutics for rare diseases, most notably Gattex/Revestive (teduglutide) for short bowel syndrome and Natpara (parathyroid hormone) for hypoparathyroidism. The company operated an internal R&D pipeline targeting rare and specialty disease indications and relied on proprietary drug development and advanced manufacturing processes. Following its 2015 acquisition by Takeda, these products are sold through Takeda's global pharmaceutical commercial organization.

Is NPS Pharmaceuticals a public or private company?

NPS Pharmaceuticals is a public company. It is classified as corporate owned and is currently operating.

When was NPS Pharmaceuticals founded?

NPS Pharmaceuticals was founded in 1986. It employs 101 to 250 people.

Where is NPS Pharmaceuticals based?

NPS Pharmaceuticals is headquartered in Bedminster, United States, in the North America region.

How does NPS Pharmaceuticals make money?

One revenue line is on record: prescription Pharmaceuticals.

Who are NPS Pharmaceuticals's main competitors?

Broad incumbents on record are Shire (now part of Takeda) and Genzyme (Sanofi Rare Disease). Direct peers are BioMarin Pharmaceutical, Vertex Pharmaceuticals, Alexion Pharmaceuticals (AstraZeneca Rare Disease), Swedish Orphan Biovitrum (Sobi), Ultragenyx Pharmaceutical and Recordati Rare Diseases. Emerging players are Amicus Therapeutics and Reata Pharmaceuticals (now Biogen).

Does NPS Pharmaceuticals have an API?

No public API is recorded for NPS Pharmaceuticals.

What industry is NPS Pharmaceuticals in?

NPS Pharmaceuticals's product category is Specialty Pharmaceuticals (Rare Disease Therapeutics). Its primary akta.pro industry code is HLAIAIAJ, Rare Endocrine & Growth Disorder Therapies, with a secondary code of HLAIAIAN, Rare Pediatric & Congenital Disorder Therapies. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
startupticker.chNLS Pharmaceutics with stuttering start at NasdaqNLS Pharmaceutics listed on Nasdaq Capital Market on January 29, 2021, raising about $20 million from an IPO of 4.8 million units at $4.15 each. The stock fell to $2.62 on Monday but closed at $2.82 on Tuesday. The company's lead product, Quilience, has orphan drug designations for narcolepsy.PR NewswireNPS Pharmaceuticals Partnering Deals and Alliances 2010 to 2017The report details the partnering deals and alliances of NPS Pharmaceuticals from 2010 to 2017, providing insights into their strategic partnerships within the life sciences sector. It highlights the importance of finding suitable partners for developing and commercializing next-generation therapies and offers data on deal types and company engagements since 2010. The report also outlines how to approach biopharma companies for partnership opportunities.PR NewswireShire Reports on Four Decades of Real-World Safety Experience With FEIBA® [Anti-Inhibitor Coagulant Complex]Shire presented an update on its safety database for FEIBA, covering 40 years of real-world use, and revealed new in vitro data showing a multi-fold increase in thrombin generation when combining an investigational procoagulant bispecific antibody with bypass therapy. The data indicate a potential thrombotic risk for patients receiving the investigational agent with an approved bypass agent.PR NewswireTolerability Data for Shire's CUVITRU Accepted for Oral Presentation at the American College Of Allergy, Asthma & Immunology Annual MeetingShire will present data on CUVITRU tolerability at the ACAAI annual meeting, showing that increased infusion volumes and rates did not raise local adverse reactions. 72% of patients achieved the maximum infusion rate of 60 mL per hour per site, and 99.8% of infusions completed without rate reduction or discontinuation.PR NewswireShire Delivers Strong Q2 2016 Revenue Growth; Upgrades OutlookShire reported Q2 2016 revenue of $2.429 billion, up 56% year-over-year, with product sales rising 57% and non-GAAP operating income up 58%. The company upgraded its full-year 2016 guidance, raising operating cost synergy expectations to at least $700 million in year three post-Baxalta close.PR NewswireShire Reinforces Commitment in Hematology with Robust Data Presented at International Congress of the World Federation of HemophiliaShire will present over 40 presentations at the WFH Congress in Orlando, showcasing its hematology portfolio including ADYNOVATE and VONVENDI. The company highlights the PROPEL study comparing ADYNOVATE at two Factor VIII trough levels and introduces a patient-reported outcome measure. VONVENDI launches commercially in the U.S. in Q3 2016.PR NewswireShire to License PF-00547659 from Pfizer, Adding to Established and Leading Gastrointestinal PortfolioShire agreed to license global rights to PF-00547659, a biologic for inflammatory bowel disease, from Pfizer. The drug completed Phase 2 trials in over 700 patients, showing increased remission and healing in ulcerative colitis. Phase 3 trials are expected to begin after regulatory consultation.PR NewswireShire Completes Combination With Baxalta Creating the Global Leader in Rare Diseases and Highly Specialized ConditionsShire completed its combination with Baxalta, creating a global biotechnology company focused on rare diseases and highly specialized conditions. The combined company expects over $20 billion in annual revenue by 2020, with rare disease products generating about 65% of total revenue. It also anticipates annual operating cost synergies of at least $500 million within three years.PR NewswireShire Completes Combination With Baxalta Creating the Global Leader in Rare Diseases and Highly Specialized ConditionsShire completed its combination with Baxalta, creating a global biotechnology company focused on rare diseases and highly specialized conditions. The combined company expects over $20 billion in annual revenue by 2020, with rare disease products generating about 65% of total revenue and $500 million in annual operating cost synergies within three years.PR NewswireShire Receives Positive CHMP Opinion in Europe for Revestive® (Teduglutide) for Paediatric Patients with Short Bowel SyndromeThe European Medicines Agency's CHMP adopted a positive opinion recommending the extension of Revestive (teduglutide) approval for paediatric patients with short bowel syndrome. The European Commission is expected to make a final decision in August 2016. The company awaits the EMA's final decision and potential new treatment option for children.